{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:52:36Z","timestamp":1780721556275,"version":"3.54.1"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T00:00:00Z","timestamp":1394668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Actinic keratoses (<jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content>) occur more commonly and behave more aggressively in renal transplant recipients (<jats:styled-content style=\"fixed-case\">RTR<\/jats:styled-content>). Topical 5% 5\u2010fluorouracil (5\u2010<jats:styled-content style=\"fixed-case\">FU<\/jats:styled-content>) cream is a commonly used agent whose efficacy and safety have never been exclusively studied in the <jats:styled-content style=\"fixed-case\">RTR<\/jats:styled-content> population before. Eight <jats:styled-content style=\"fixed-case\">RTR<\/jats:styled-content> were enrolled and 5% 5\u2010<jats:styled-content style=\"fixed-case\">FU<\/jats:styled-content> cream applied to <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content> lesions on their face twice daily for 3 weeks. They were reviewed at 2 and 8 weeks, and 12 months post\u2010commencement of treatment. Their <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content> were counted and their cumulative surface areas measured. Patients completed surveys monitoring adverse effects and tolerability. Complete (100%) and partial clearance (\u2265\u200975%) rates were measured, as well as mean percentages of the reduction in AK surface area. Patients had complete clearance rates of 63 and 0% at 8 weeks and 12 months, respectively. All (100%) patients had partial clearance at week 8 and 71% had partial clearance at 12 months. Patients had on average 15 <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content> at week 0 and 1 and 3 at 8 weeks and 12 months, respectively. The mean <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content> clearance rate was 98% at week 8 and 79% at 12 months. Common side\u2010effects were erythema, itch and flaking or scaling, mostly mild in severity. 5\u2010<jats:styled-content style=\"fixed-case\">FU<\/jats:styled-content> appears to be an efficacious and safe treatment for <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">RTR<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/ajd.12158","type":"journal-article","created":{"date-parts":[[2014,3,14]],"date-time":"2014-03-14T03:08:55Z","timestamp":1394766535000},"page":"204-208","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The efficacy and safety of topical 5% 5\u2010fluorouracil in renal transplant recipients for the treatment of actinic keratoses"],"prefix":"10.1111","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-8812","authenticated-orcid":false,"given":"Annabel I.","family":"Ingham","sequence":"first","affiliation":[{"name":"Medical School The University of Adelaide  Adelaide South Australia Australia"},{"name":"Department of Dermatology Royal Adelaide Hospital  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Weightman","sequence":"additional","affiliation":[{"name":"Medical School The University of Adelaide  Adelaide South Australia Australia"},{"name":"Department of Dermatology The Queen Elizabeth Hospital  Woodville South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,3,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)70265-2"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07454.x"},{"key":"e_1_2_6_4_1","volume-title":"ANZDATA. Thirty\u2010Fourth Annual Report","author":"McDonald S","year":"2011"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08269.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1684\/ejd.2010.1010","article-title":"Results of a randomized, placebo\u2010controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses","volume":"20","author":"Ulrich C","year":"2010","journal-title":"Eur. J. Dermatol."},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07616.x"},{"key":"e_1_2_6_8_1","first-page":"1275","article-title":"Development of malignancy following renal transplantation in Australia and New Zealand","volume":"24","author":"Sheil AG","year":"1992","journal-title":"Transplant. Proc."},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04976.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181ec7228"},{"key":"e_1_2_6_11_1","first-page":"225","volume-title":"Skin Cancer Management \u2013 A Practical Approach","author":"Carucci J","year":"2010"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92459-S"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-0960.2002.00613.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.04045.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08271.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.8.976"}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajd.12158","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.12158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T22:39:40Z","timestamp":1696459180000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajd.12158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,13]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1111\/ajd.12158"],"URL":"https:\/\/doi.org\/10.1111\/ajd.12158","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,13]]},"assertion":[{"value":"2013-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-02-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-03-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}